Pfizer sharpens prostate cancer case with Talzenna win — oncology

Key Takeaways

• TALAPRO-3 met its primary rPFS endpoint in HRR-mutated mCSPC with HR 0.48 (95% CI 0.36–0.65; p < 0.0001), per Pfizer's ASCO 2026 disclosure.
• Estimated 3-year rPFS was 77% with Talzenna plus Xtandi versus 56% with placebo plus Xtandi after more than 37 months' median follow-up.
• The trial randomized 599 patients with confirmed HRR alterations (HRR12 panel), correcting earlier secondary reports that described an unselected all-comers design.
• Talzenna plus Xtandi already holds a June 2023 FDA approval in HRR-mutated mCRPC; TALAPRO-3 is a Phase 3 readout, not a new label.

What did Pfizer report from TALAPRO-3?

Pfizer said Talzenna (talazoparib) plus Xtandi (enzalutamide) improved radiographic progression-free survival versus placebo plus Xtandi in homologous recombination repair (HRR) gene-mutated metastatic castration-sensitive prostate cancer (mCSPC / mHSPC).

In the Pfizer ASCO 2026 press release, the company reported a 52% reduction in risk of radiographic progression or death (HR 0.48; 95% CI 0.36–0.65; p < 0.0001). Three-year rPFS rates were estimated at 77% versus 56%. Median rPFS was not reached on the combination arm and was 46 months on control.

Results were presented as late-breaking abstract LBA5007 at ASCO 2026 and published simultaneously in The New England Journal of Medicine, according to Pfizer.

Who was enrolled, and was it an all-comers trial?

No. TALAPRO-3 was biomarker-selected for HRR alterations.

Pfizer states the multicenter, randomized, double-blind study enrolled 599 patients with mCSPC who had alterations in one or more HRR genes on the trial's HRR12 panel and had received ≤3 months of androgen-deprivation therapy with or without an approved AR pathway inhibitor.

Patients were randomized to Talzenna 0.5 mg/day plus Xtandi 160 mg/day or placebo plus Xtandi 160 mg/day. The protocol is registered as NCT04821622 on ClinicalTrials.gov.

How do the numbers break down by BRCA status?

Pfizer reported consistent rPFS benefit across BRCA and non-BRCA HRR subgroups in its ASCO disclosure.

Estimated 3-year rPFS was 77% versus 49% in BRCA-altered disease (HR 0.37; 95% CI 0.22–0.61) and 76% versus 60% in non-BRCA HRR alterations (HR 0.57; 95% CI 0.39–0.82), each versus placebo plus Xtandi.

Overall survival remained immature in the company readout, with a trend favoring the combination that had not crossed a final OS claim in the press materials reviewed for this article.

How does this relate to the existing FDA Talzenna label?

In June 2023, FDA approved Talzenna with Xtandi for adults with HRR gene-mutated metastatic castration-resistant prostate cancer (mCRPC), based on TALAPRO-2.

In June 2025, FDA updated labeling with final OS data for that HRR-mutated mCRPC indication but did not expand to non-HRR mCRPC, and Pfizer said it would not further pursue that broader mCRPC expansion in the United States.

TALAPRO-3 moves the same PARP-plus-ARPI pairing earlier, into castration-sensitive disease, still gated on HRR alterations. Regulatory filings for that setting were not confirmed as approved in the primary materials used here.

What should BD and oncology strategy teams watch next?

Watch whether Pfizer and Astellas file for an mCSPC / mHSPC indication in the United States and Europe, and how payers treat genetic testing mandates tied to HRR12-style panels.

Compare toxicity and discontinuation rates against AMPLITUDE and other PARPi-plus-ARPI intensification programs before assuming a class-wide standard of care.

Track final OS maturity and any FDA briefing documents that quantify myelosuppression trade-offs against the 52% rPFS risk reduction.

What remains unproven after the ASCO 2026 readout?

TALAPRO-3 does not prove benefit in HRR-negative mCSPC. Earlier secondary summaries that described an unselected all-comers enrollment contradict Pfizer's and ClinicalTrials.gov descriptions and should not be relied on.

A statistically definitive overall survival win was not claimed in the Pfizer ASCO release reviewed for this rewrite. Three-year OS trends need longer follow-up before survival-based positioning.

Practice-changing status also depends on label language, companion diagnostics, and whether non-BRCA HRR subgroups retain a favorable benefit-risk profile under real-world hematologic monitoring.

Related NovaPharma coverage

• Pfizer danuglipron Phase 3 / Phase 2b obesity program coverage
• Pfizer danuglipron Phase 2b obesity endpoint
• Talazoparib tosylate drug profile

Frequently Asked Questions

Primary Sources

1. Pfizer — TALZENNA plus XTANDI TALAPRO-3 ASCO 2026 results
2. ClinicalTrials.gov — TALAPRO-3 (NCT04821622)
3. Pfizer — FDA approval of TALZENNA with XTANDI in HRR-mutated mCRPC (June 2023)